Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Large ribosomal subunit protein uL22 is a highly conserved structural component of the bacterial 50S ribosomal subunit, encoded by the rplV gene. It plays a critical role in ribosome assembly by interacting with the 23S rRNA and other ribosomal proteins, facilitates the folding of rRNA, and forms an important part of the ribosomal exit tunnel through which newly synthesized polypeptides emerge. uL22 is essential for protein synthesis and is a key target for several antibiotic classes, primarily macrolides such as erythromycin. Mutations in uL22 can cause resistance to these antibiotics by altering tunnel structure and thus diminishing drug binding. Although not a human therapeutic target, uL22 is highly relevant in the context of bacterial infection and antibiotic therapy.
Drugs bind to the ribosomal exit tunnel (lined in part by uL22), blocking passage of the nascent polypeptide and inhibiting protein synthesis. Mutations in uL22 alter tunnel conformation and can reduce drug binding, leading to resistance.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Large ribosomal subunit protein uL22 (uL22).